Difference between revisions of "Daunorubicin (Cerubidine)"
Warner-admin (talk | contribs) |
|||
| Line 13: | Line 13: | ||
==Toxicity information== | ==Toxicity information== | ||
| − | *Per Feijen et al. 2015 <ref>Feijen EA, Leisenring WM, Stratton KL, Ness KK, van der Pal HJ, Caron HN, Armstrong GT, Green DM, Hudson MM, Oeffinger KC, Robison LL, Stovall M, Kremer LC, Chow EJ. Equivalence Ratio for Daunorubicin to Doxorubicin in Relation to Late Heart Failure in Survivors of Childhood Cancer. J Clin Oncol. 2015 Nov 10;33(32):3774-80. Epub 2015 Aug 24.[http:// | + | *Per Feijen et al. 2015 <ref>Feijen EA, Leisenring WM, Stratton KL, Ness KK, van der Pal HJ, Caron HN, Armstrong GT, Green DM, Hudson MM, Oeffinger KC, Robison LL, Stovall M, Kremer LC, Chow EJ. Equivalence Ratio for Daunorubicin to Doxorubicin in Relation to Late Heart Failure in Survivors of Childhood Cancer. J Clin Oncol. 2015 Nov 10;33(32):3774-80. Epub 2015 Aug 24. [https://doi.org/10.1200/jco.2015.61.5187 link to original article] [http://www.ncbi.nlm.nih.gov/pmc/articles/pmc4737860/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/26304888 PubMed] |
</ref>, daunorubicin appears to be significantly less cardiotoxic than doxorubicin in survivors of childhood cancer. | </ref>, daunorubicin appears to be significantly less cardiotoxic than doxorubicin in survivors of childhood cancer. | ||
==Patient drug information== | ==Patient drug information== | ||
Revision as of 12:19, 14 April 2021
General information
Class/mechanism: Anthracycline, binds and intercalates between DNA base pairs. Inhibits topoisomerase II activity by stabilizing the DNA-topoisomerase II complex, resulting in single and double strand DNA breaks. May also inhibit polymerase activity and trigger free radical damage to DNA.[1][2]
Route: IV
Extravasation: vesicant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- B-cell acute lymphoblastic leukemia
- Acute myeloid leukemia
- Acute promyelocytic leukemia
- T-cell acute lymphoblastic leukemia
Toxicity information
- Per Feijen et al. 2015 [3], daunorubicin appears to be significantly less cardiotoxic than doxorubicin in survivors of childhood cancer.
Patient drug information
- Daunorubicin (Cerubidine) patient drug information (Chemocare)[4]
- Daunorubicin (Cerubidine) patient drug information (UpToDate)[5]
History of changes in FDA indication
- 12/19/1979: Initial FDA approval
Patient Information
Also known as
- Generic name: daunomycin
- Brand names: Cerubidin, Cerubidine, D-Blastin, Daunoblastin, Daunoblastina, Daunocin, Daunomicina, Daunorubicine, Daurocina, Maxidauno, Ondena, Rubidomycin, Rubilem, Rubomycin, Runabicon
References
- ↑ 1.0 1.1 1.2 Daunorubicin (Cerubidine) package insert
- ↑ Daunorubicin (Cerubidine) package insert (locally hosted backup)
- ↑ Feijen EA, Leisenring WM, Stratton KL, Ness KK, van der Pal HJ, Caron HN, Armstrong GT, Green DM, Hudson MM, Oeffinger KC, Robison LL, Stovall M, Kremer LC, Chow EJ. Equivalence Ratio for Daunorubicin to Doxorubicin in Relation to Late Heart Failure in Survivors of Childhood Cancer. J Clin Oncol. 2015 Nov 10;33(32):3774-80. Epub 2015 Aug 24. link to original article link to PMC article PubMed
- ↑ Daunorubicin (Cerubidine) patient drug information (Chemocare)
- ↑ Daunorubicin (Cerubidine) patient drug information (UpToDate)